Coating of adeno‐associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera
- 28 January 2008
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 10 (4) , 400-411
- https://doi.org/10.1002/jgm.1161
Abstract
Background Copolymers based on poly‐[N‐(2‐hydroxypropyl) methacrylamide] (HPMA) have been used previously to enable targeted delivery of adenovirus. Here we demonstrate polymer‐coating techniques can also be used to modify and retarget adeno‐associated virus (AAV) types 5 and 8. Methods Three strategies for modifying transductional targeting of AAV were employed. The first involved direct reaction of AAV5 or AAV8 with amino‐reactive HPMA copolymer. The second approach used carbodiimide (EDC) chemistry to increase the number of surface amino groups on the AAV5 capsid, thereby improving coating efficiency. In the third approach, the AAV5 genome was isolated from capsid proteins and delivered in a synthetic polyplex consisting of polyethylenimine (PEI) and HPMA. Results Efficient covalent attachment of HPMA copolymer to AAV5 could only be achieved following modification of the virus with EDC. Coating inhibited sialic acid dependent infection and provided a platform for retargeting via new ligands, including basic fibroblast growth factor. Retargeted infection was shown to be partially resistant to neutralising antisera. Delivery of AAV5 genomes using PEI and HPMA was efficient and provided absolute control of tropism and protection from antisera. In contrast AAV8 could be reacted directly with HPMA copolymer and allowed specific retargeting via the epidermal growth factor receptor, but gave no protection against neutralising antisera. Conclusions Reactive HPMA polymers can be used to ablate the natural tropism of both AAV8 and EDC‐modified AAV5 and enable receptor‐specific infection by incorporation of targeting ligands. These data show transductional targeting strategies can be used to improve the versatility of AAV vectors. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Metabolic Biotinylation Provides a Unique Platform for the Purification and Targeting of Multiple AAV Vector SerotypesMolecular Therapy, 2006
- High Levels of Persistent Expression of α1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated VirusesMolecular Therapy, 2006
- Antitumor efficacy of AAV-mediated systemic delivery of interferon-βCancer Gene Therapy, 2005
- Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heartNature Biotechnology, 2005
- Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked LigandsJournal of Virology, 2002
- Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial CellsMolecular Therapy, 2001
- Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus CapsidsMolecular Therapy, 2001
- Building a Better Vector: The Manipulation of AAV VirionsVirology, 2000
- AAV vectors: is clinical success on the horizon?Gene Therapy, 2000
- Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2Nature Medicine, 1999